BiomX (NYSEAMERICAN:PHGE) Given New $26.00 Price Target at HC Wainwright

BiomX (NYSEAMERICAN:PHGE) had its price objective hoisted by HC Wainwright to $26.00 in a research note issued on Tuesday, November 25th,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 476.50% from the company’s previous close. HC Wainwright also issued estimates for BiomX’s Q4 2025 earnings at ($4.61) EPS, FY2025 earnings at ($19.80) EPS, FY2026 earnings at ($5.85) EPS, FY2027 earnings at ($6.01) EPS and FY2028 earnings at ($4.57) EPS.

BiomX Trading Down 4.0%

NYSEAMERICAN:PHGE traded down $0.19 on Tuesday, hitting $4.51. The company’s stock had a trading volume of 48,756 shares, compared to its average volume of 88,820. The firm has a market capitalization of $6.90 million, a P/E ratio of -0.18 and a beta of 1.56. BiomX has a one year low of $4.10 and a one year high of $22.06. The stock has a fifty day moving average of $8.58 and a two-hundred day moving average of $8.95.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).